Terms ending in 2034
Every in-force patent on Merck Sharp and Dohme LLC's record whose computed term ends in 2034, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 9,315,475 | HIV Protease Inhibitors In force · High confidence | Merck Sharp & Dohme LLC | In force | High confidence | |
| US 9,550,786 | 4-Fluoropiperidine Orexin Receptor Antagonists In force · High confidence | Merck Sharp & Dohme LLC | In force | High confidence | |
| US 9,446,130 | BTK Inhibitors In force · High confidence | Merck Sharp & Dohme LLC | In force | High confidence | |
| US 9,394,308 | Inhibiting the Transient Receptor Potential A1 Ion Channel In force · High confidence | Merck Sharp & Dohme LLC | In force | High confidence | |
| US 9,481,682 | Substituted Benzamides and Substituted Pyridinecarboxamides as BTK Inhibitors In force · High confidence | Merck Sharp & Dohme LLC | In force | High confidence | |
| US 9,540,377 | 2,6,7,8 Substituted Purines as HDM2 Inhibitors In force · High confidence | Merck Sharp & Dohme LLC | In force | High confidence | |
| US 9,242,998 | Tetracyclic Heterocycle Compounds and Methods of Use Thereof for the Treatment of Hepatitis C In force · High confidence | Merck Sharp & Dohme LLC | In force | High confidence | |
| US 9,243,002 | Tetracyclic Heterocycle Compounds and Methods of Use Thereof for the Treatment of Hepatitis C In force · High confidence | Merck Sharp & Dohme LLC | In force | High confidence | |
| US 9,493,461 | Tetracyclic Heterocycle Compounds and Methods of Use Thereof for the Treatment of Hepatitis C In force · High confidence | Merck Sharp & Dohme LLC | In force | High confidence | |
| US 9,682,978 | 2,6,7 Substituted Purines as HDM2 Inhibitors In force · High confidence | Merck Sharp & Dohme LLC | In force | High confidence | |
| 152 more term ends in 2034 · Pro | |||||
10 of 162 patents shown. Soonest term end first, then patent number.
Pro members see all 162.
155 of these are in force and held by Merck Sharp and Dohme LLC.
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.